Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| 1 |
Keurig Dr Pepper
KDP
|
+$884M |
| 2 |
Amazon
AMZN
|
+$342M |
| 3 |
Automatic Data Processing
ADP
|
+$228M |
| 4 |
Evergy
EVRG
|
+$224M |
| 5 |
Chevron
CVX
|
+$211M |
Top Sells
| 1 |
Bank of America
BAC
|
+$280M |
| 2 |
Mondelez International
MDLZ
|
+$239M |
| 3 |
Abbott
ABT
|
+$230M |
| 4 |
EGN
Energen
EGN
|
+$178M |
| 5 |
American International
AIG
|
+$170M |
Sector Composition
| 1 | Financials | 15.43% |
| 2 | Technology | 13.05% |
| 3 | Healthcare | 12.23% |
| 4 | Consumer Discretionary | 10.26% |
| 5 | Industrials | 9.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
1726
DELISTED
Invitae Corporation
NVTA
| $3.94M | 0.01% |
536,056
+468,596
| +695% | +$3.44M |
|
|
CRZO
1727
DELISTED
Carrizo Oil & Gas Inc
CRZO
| $3.93M | 0.01% |
+141,036
| New | +$3.93M |
|
|
AVLR
1728
DELISTED
Avalara, Inc.
AVLR
| $3.92M | 0.01% |
+73,445
| New | +$3.92M |
|
|
CY
1729
DELISTED
Cypress Semiconductor
CY
| $3.91M | 0.01% |
251,148
-3,062,346
| -92% | -$47.7M |
|
1730
Larimar Therapeutics
LRMR
$336M
| $3.91M | 0.01% |
31,860
+16,766
| +111% | +$2.06M |
|
|
AUTL
1731
Autolus Therapeutics
AUTL
$381M
| $3.91M | 0.01% |
+145,945
| New | +$3.91M |
|
1732
Akebia Therapeutics
AKBA
$782M
| $3.9M | 0.01% |
390,970
-267,052
| -41% | -$2.67M |
|
1733
Mesa Laboratories
MLAB
$339M
| $3.89M | 0.01% |
+18,418
| New | +$3.89M |
|
|
MIXT
1734
DELISTED
MIX TELEMATICS LIMITED
MIXT
| $3.89M | 0.01% |
219,264
+132,747
| +153% | +$2.35M |
|
|
ECOM
1735
DELISTED
CHANNELADVISOR CORPORATION
ECOM
| $3.87M | 0.01% |
275,386
+168,252
| +157% | +$2.36M |
|
|
UCFC
1736
DELISTED
United Community Financial Corp
UCFC
| $3.86M | 0.01% |
351,403
+156,108
| +80% | +$1.72M |
|
1737
Televisa
TV
$1.54B
| $3.86M | 0.01% |
203,626
-602,505
| -75% | -$11.4M |
|
1738
Vanguard Total International Bond ETF
BNDX
$68.4B
| $3.85M | 0.01% |
70,412
-2,777
| -4% | -$152K |
|
1739
Addus HomeCare
ADUS
$2.03B
| $3.84M | 0.01% |
67,137
+55,719
| +488% | +$3.19M |
|
|
HMLP
1740
DELISTED
HOEGH LNG PARTNERS LP
HMLP
| $3.84M | 0.01% |
213,790
-110,936
| -34% | -$1.99M |
|
|
SYRS
1741
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.83M | 0.01% |
37,547
+21,170
| +129% | +$2.16M |
|
1742
Cytokinetics
CYTK
$6.12B
| $3.83M | 0.01% |
461,733
+359,561
| +352% | +$2.98M |
|
|
BNCL
1743
DELISTED
Beneficial Bancorp, Inc.
BNCL
| $3.83M | 0.01% |
236,111
+96,289
| +69% | +$1.56M |
|
|
ABAX
1744
DELISTED
Abaxis Inc
ABAX
| $3.83M | 0.01% |
46,075
-17,597
| -28% | -$1.46M |
|
|
GCAP
1745
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $3.82M | 0.01% |
506,240
+479,134
| +1,768% | +$3.62M |
|
|
BHVN
1746
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.81M | 0.01% |
96,491
-24,488
| -20% | -$968K |
|
1747
Medpace
MEDP
$13.8B
| $3.81M | 0.01% |
+88,651
| New | +$3.81M |
|
1748
NBT Bancorp
NBTB
$2.27B
| $3.81M | 0.01% |
99,821
-162,122
| -62% | -$6.18M |
|
|
APTI
1749
DELISTED
Apptio, Inc. Class A Common Stock
APTI
| $3.81M | 0.01% |
105,145
-795,010
| -88% | -$28.8M |
|
1750
Corvus Pharmaceuticals
CRVS
$434M
| $3.79M | ﹤0.01% |
345,574
-259,729
| -43% | -$2.85M |
|